|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.30 HKD | +0.83% |
|
-5.61% | +7.09% |
| 01-22 | Genscript Biotech Associate Books $555 Million in Q4 CARVYKTI Sales | MT |
| 15/10/25 | GenScript Associate Books $524 Million in Q3 CARVYKTI Sales | MT |
| Capitalization | 3.73B 29.08B 3.17B 2.94B 2.75B 5.12B 343B 5.43B 33.6B 13.34B 162B 13.98B 13.7B 588B | P/E ratio 2025 * |
54.9x | P/E ratio 2026 * | 42.3x |
|---|---|---|---|---|---|
| Enterprise value | 3.54B 27.58B 3.01B 2.79B 2.61B 4.86B 325B 5.15B 31.86B 12.65B 153B 13.26B 12.99B 558B | EV / Sales 2025 * |
3.72x | EV / Sales 2026 * | 4.29x |
| Free-Float |
54.04% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Genscript Biotech Corporation
| 1 day | +0.83% | ||
| 1 week | -5.61% | ||
| Current month | +7.09% | ||
| 1 month | +0.23% | ||
| 3 months | -15.93% | ||
| 6 months | -26.76% | ||
| Current year | +7.09% |
| 1 week | 13 |  | 14.1 |
| 1 month | 12.28 | | 14.6 |
| Current year | 12.4 | | 14.6 |
| 1 year | 9.45 | | 19.4 |
| 3 years | 7.43 | | 30 |
| 5 years | 7.43 | | 43.4 |
| 10 years | 1.07 | | 43.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ye Wang
PSD | President | 57 | 01/12/2017 |
Weihui Shao
CEO | Chief Executive Officer | - | 01/01/2023 |
Jian Ge Meng
DFI | Director of Finance/CFO | 57 | 01/04/2010 |
| Director | Title | Age | Since |
|---|---|---|---|
Ye Wang
BRD | Director/Board Member | 57 | 21/05/2015 |
Jian Ge Meng
CHM | Chairman | 57 | 22/11/2020 |
Li Zhu
BRD | Director/Board Member | 76 | 22/11/2020 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.83% | -5.61% | +25.95% | -51.99% | 3.73B | |
| +0.04% | -0.68% | -4.77% | +12.20% | 49.48B | |
| -1.56% | -1.00% | +14.23% | +2.87% | 40.07B | |
| +0.15% | +0.33% | +52.68% | +26.14% | 37.55B | |
| +1.92% | +1.44% | +23.10% | +42.46% | 31.67B | |
| -0.99% | -2.20% | +185.93% | +328.06% | 22.74B | |
| -3.01% | -3.74% | +69.03% | +145.51% | 16.56B | |
| Average | -0.37% | -1.19% | +52.31% | +72.18% | 28.83B | |
| Weighted average by Cap. | -0.31% | -0.38% | +42.18% | +63.04% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 951M 7.41B 809M 750M 700M 1.31B 87.36B 1.38B 8.57B 3.4B 41.25B 3.57B 3.49B 150B | 811M 6.32B 689M 639M 597M 1.11B 74.48B 1.18B 7.3B 2.9B 35.17B 3.04B 2.98B 128B |
| Net income | 65.9M 514M 56.05M 51.95M 48.55M 90.51M 6.05B 95.93M 594M 236M 2.86B 247M 242M 10.4B | 87.98M 686M 74.83M 69.36M 64.82M 121M 8.08B 128M 793M 315M 3.82B 330M 323M 13.88B |
| Net Debt | -193M -1.5B -164M -152M -142M -265M -17.71B -281M -1.74B -690M -8.36B -723M -708M -30.42B | -252M -1.96B -214M -199M -186M -346M -23.14B -367M -2.27B -901M -10.93B -944M -925M -39.75B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/01/26 | 13.30 $ | +0.83% | 9,155,017 |
| 22/01/26 | 13.19 $ | -6.12% | 16,732,800 |
| 21/01/26 | 14.05 $ | +2.03% | 5,442,365 |
| 20/01/26 | 13.77 $ | -0.51% | 4,497,850 |
| 19/01/26 | 13.84 $ | -1.77% | 8,331,825 |
Delayed Quote Hong Kong S.E., January 23, 2026 at 04:08 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 1548 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition